Related Experiment Videos
[Activation of hemostasis in patients with chronic cholecystitis]
J Kłoczko1, J J Lewandowski, M Galar
1Klinika Hematologii AM w Białymstoku.
Insights
Patients with chronic cholecystitis exhibit hypercoagulability, indicated by elevated levels of key hemostasis markers like prothrombin fragments (F1+2), thrombin/antithrombin complex (TAT), and D-dimer.
Area of Science:
- Medical research
- Hematology
- Gastroenterology
Background:
- Chronic cholecystitis is a common gallbladder condition.
- Alterations in hemostasis may be associated with inflammatory diseases.
Purpose of the Study:
- To investigate the impact of chronic cholecystitis on blood coagulation.
- To assess specific hemostasis markers in patients with chronic cholecystitis.
Main Methods:
- Study included 48 patients with chronic cholecystolithiasis undergoing cholecystectomy.
- A control group of 25 healthy individuals was used for comparison.
- Plasma concentrations of prothrombin fragments (F1+2), thrombin/antithrombin complex (TAT), and D-dimer were measured.
Main Results:
- Patients with chronic cholecystitis demonstrated hypercoagulability.
- Elevated plasma levels of F1+2, TAT, and D-dimer were observed in the patient group.
- These markers are sensitive indicators of hemostasis activation.
Conclusions:
- Chronic cholecystitis is associated with an activated coagulation system.
- Increased levels of hemostasis markers suggest a prothrombotic state in these patients.
Abstract:
The aim of the study was to evaluate the influence of chronic cholecystitis on haemostasis. The study was conducted on 48 patients suffering from chronic cholecystolithiasis admitted for cholecystectomy to the Department of Surgery Regional Hospital in Białystok. The control group consisted of 25 healthy subjects in this same age range. As a result of the study we found out that patients with chronic cholecystitis had hypercoagulability characterised by increase plasma concentrations of the sensitive markers of haemostasis: prothrombin fragments (F1 + 2), thrombin/antithrombin complex (TAT) and D-dimer.